Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.86 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28008696 | 0.96 | CYP4F2 (0.81) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL22098182 | 0.93 | CYP4F2 (1.00) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL22070564 | 0.93 | CYP4F2 (0.76) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL28008697 | 0.91 | CYP4F2 (0.73) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL11587953 | 0.91 | CYP4F2 (0.73) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL8852291 | 0.91 | CYP4F2 (0.73) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4842643 | 0.91 | CYP4F2 (0.73) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL13948404 | 0.91 | CYP4F2 (0.73) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL20730201 | 0.90 | CYP4F2 (0.77) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4842634 | 0.90 | CYP4F2 (0.71) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118903087-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114126593-B | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4003314-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2021021563-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| EP-3728119-A1 | EMM-31 MATERIALS AND PROCESSES AND USES THEREOF | ExxonMobil Research and Engineering Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10710889-B2 | EMM-31 materials and processes and uses thereof | EXXONMOBIL RESEARCH & ENGINEERING COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710889-B2 | EMM-31 materials and processes and uses thereof | EXXONMOBIL RESEARCH & ENGINEERING COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190194028-A1 | EMM-31 MATERIALS AND PROCESSES AND USES THEREOF | EXXONMOBIL RES & ENG CO (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194028-A1 | EMM-31 MATERIALS AND PROCESSES AND USES THEREOF | EXXONMOBIL RES & ENG CO (US) | 2019-06-27 | — | — | US | disclosed |
| EP-2479203-A1 | AROMATIC POLYESTER | Muroran Institute of Technology (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172570-A1 | AROMATIC POLYESTER | NITTA CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-8129493-B2 | Aromatic polyester | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CYP4F2 708/4885CYP4A11 659/4885ALDH1A1 284/4885 |
| US-20190194028-A1 | EMM-31 MATERIALS AND PROCESSES AND USES THEREOF | CD14, MASP2, FGB | CYP4F2 3509/4885CYP4A11 3618/4885ALDH1A1 4767/4885 |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CYP4F2 708/4885CYP4A11 659/4885ALDH1A1 283/4885 |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | F12, PHAX, WDR82 | CYP4F2 2876/4885CYP4A11 1392/4885ALDH1A1 1882/4885 |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | CYP4F2 708/4885CYP4A11 659/4885ALDH1A1 283/4885 |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CYP4F2 708/4885CYP4A11 659/4885ALDH1A1 283/4885 |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | CYP4F2 708/4885CYP4A11 659/4885ALDH1A1 284/4885 |
| US-10710889-B2 | EMM-31 materials and processes and uses thereof | CD14, MASP2, FGB | CYP4F2 3509/4885CYP4A11 3618/4885ALDH1A1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.